Nyxoah S.A. (NYXH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Nyxoah S.A. (NYXH) Healthcare & Pipeline Overview

Nyxoah S.A. is a medical technology company based in Belgium, specializing in advanced solutions for sleep-disordered breathing. The company develops and commercializes the Genio system, a CE-Marked, patient-centric hypoglossal neurostimulation therapy designed to treat moderate to severe obstructive sleep apnea, positioning it within the innovative medical instruments and supplies sector.

What Is the Investment Thesis for NYXH?

Nyxoah S.A. presents an investment thesis centered on its innovative Genio system, a CE-Marked hypoglossal neurostimulation therapy for moderate to severe obstructive sleep apnea. The company operates in the growing medical instruments and supplies sector, addressing a significant global health issue. Key value drivers include the Genio system's patient-centric design and its potential to improve treatment adherence compared to conventional therapies, which could drive market adoption. The CE-Mark status facilitates commercialization in European markets, providing a foundation for revenue generation. However, the company currently exhibits a significant negative profit margin of -527.8%, indicating substantial ongoing operational losses relative to revenue, alongside a gross margin of 48.3%. With a market capitalization of $0.11 billion, Nyxoah is a relatively small-cap entity, and its Beta of 1.58 suggests higher volatility compared to the broader market. Future growth catalysts depend on expanding the Genio system's market penetration, potentially securing regulatory approvals in additional major markets, and demonstrating sustained clinical outcomes to drive physician and patient acceptance. Investors may want to evaluate the inherent risks associated with early-stage medical technology companies, including capital requirements for commercialization and R&D, and the competitive landscape for sleep apnea treatments.

Based on FMP financials and quantitative analysis

NYXH Key Highlights

Market Capitalization of $0.11 billion, reflecting its status as a small-cap medical technology company.

• Profit Margin of -527.8%, indicating significant operational losses as the company invests in commercialization and development.
• Gross Margin of 48.3%, demonstrating a healthy margin on its product sales before operating expenses.
• Beta of 1.58, suggesting higher volatility compared to the broader market, which may appeal to investors seeking higher risk/reward profiles.
• A dedicated workforce of 183 employees, focused on the development and commercialization of sleep-disordered breathing solutions.

Who Are NYXH's Competitors?

NYXH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NYXH's Key Strengths?

CE-Marked Genio system, validating its safety and efficacy in European markets.

• Patient-centric design of the Genio system, potentially leading to higher treatment adherence.
• Specialized hypoglossal neurostimulation technology addressing a significant unmet medical need.
• Focus on a growing market of patients with moderate to severe obstructive sleep apnea.

What Are NYXH's Weaknesses?

Significant negative profit margin (-527.8%), indicating substantial ongoing losses.

• Relatively small market capitalization ($0.11B), suggesting a smaller scale and potentially higher risk.
• High dependence on the commercial success and adoption of a single primary product, the Genio system.
• Potential for high capital requirements for continued R&D and market expansion.

What Could Drive NYXH Stock Higher?

NYXH catalyst: Commercialization of the Genio system in markets where it holds CE-Mark status, focusing on increasing patient access and adoption.

• Continued development and refinement of hypoglossal neurostimulation therapy to enhance efficacy and patient experience.
• Potential for further market penetration and expansion of the Genio system into new geographic regions, subject to regulatory approvals.

What Are the Key Risks for NYXH?

Financial-distress signal — its Altman Z-Score of -3.04 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant operating losses, as evidenced by a profit margin of -527.8%, indicating substantial capital requirements for continued operations and growth.
• Intense competition within the sleep-disordered breathing treatment market from established and emerging therapies.
• Regulatory challenges and the complex approval processes required for market access in new territories or for product enhancements.
• High dependence on the commercial success and widespread adoption of the Genio system as the company's primary product.

What Are the Growth Opportunities for NYXH?

• Market Penetration and Adoption of the Genio System: Nyxoah's primary growth opportunity lies in expanding the market penetration and adoption of its CE-Marked Genio system within existing European markets. With obstructive sleep apnea affecting a significant portion of the adult population globally, and many patients struggling with adherence to traditional therapies like CPAP, there is a substantial addressable market for alternative, patient-centric solutions. By increasing awareness among healthcare professionals and patients, securing favorable reimbursement policies, and demonstrating long-term clinical benefits, Nyxoah can drive higher utilization rates. This strategy focuses on maximizing the commercial potential of its already approved product, leveraging its unique hypoglossal neurostimulation technology to capture a larger share of the sleep apnea treatment market.
• Geographic Expansion into New Regulatory Markets: A significant growth avenue for Nyxoah involves pursuing regulatory approvals and subsequent commercialization of the Genio system in major markets beyond its current CE-Marked regions. Gaining market access in territories such as the United States, which represents a substantial medical device market, or other key global regions, could unlock considerable revenue potential. This expansion would require navigating complex regulatory pathways, conducting additional clinical trials if necessary, and establishing new distribution and sales infrastructure. Successfully entering these new markets would diversify Nyxoah's revenue streams and significantly broaden its patient reach, capitalizing on the global prevalence of moderate to severe obstructive sleep apnea.
• Product Innovation and Portfolio Expansion: While the Genio system is Nyxoah's flagship product, ongoing research and development into next-generation devices or expanded indications could serve as a vital growth driver. This could involve enhancing the Genio system's features, improving its implant procedure, or exploring its applicability to other sleep-disordered breathing conditions or patient populations. Developing a pipeline of complementary products or advanced versions of the Genio system would strengthen Nyxoah's competitive position, cater to a wider range of patient needs, and potentially extend the product's lifecycle. Such innovation would demonstrate the company's commitment to leadership in neurostimulation therapy for sleep disorders.
• Strategic Partnerships and Collaborations: Forming strategic alliances with larger medical device companies, pharmaceutical firms, or specialized distribution networks could accelerate Nyxoah's market access and commercialization efforts. Collaborations could provide access to broader sales forces, established market channels, and additional capital for R&D or market expansion. For instance, partnering with a company that has a strong presence in sleep diagnostics or respiratory care could create synergistic opportunities for patient identification and integrated treatment pathways. These partnerships could significantly enhance Nyxoah's operational scale and market reach, allowing it to penetrate new segments more efficiently than through organic growth alone.
• Addressing the Untreated and Underdiagnosed OSA Population: A substantial portion of individuals suffering from obstructive sleep apnea remain undiagnosed or untreated, representing a vast untapped market. Nyxoah has an opportunity to contribute to and benefit from increased public and medical community awareness regarding OSA and its health implications. By supporting initiatives that promote early diagnosis and highlight the availability of advanced treatments like the Genio system, Nyxoah can expand the overall addressable market. Educational campaigns targeting primary care physicians, sleep specialists, and the general public could drive more patients into the diagnostic and treatment funnel, positioning the Genio system as a leading solution for those seeking effective alternatives.

What Threats Does NYXH Face?

• Intense competition from established and emerging therapies for obstructive sleep apnea.
• Regulatory hurdles and lengthy approval processes for new markets or product enhancements.
• Challenges in securing favorable reimbursement policies for its innovative therapy.
• Potential for unforeseen clinical trial risks or adverse events impacting product reputation and adoption.

What Are NYXH's Competitive Advantages?

• Proprietary hypoglossal neurostimulation technology embodied in the Genio system.
• CE-Mark status, validating the product's safety and efficacy for European markets.
• Patient-centric design aimed at improving adherence, a key differentiator in OSA treatment.
• Intellectual property surrounding its specialized medical device and therapeutic approach.

What Does NYXH Do?

Nyxoah S.A., established in 2009 and headquartered in Mont-Saint-Guibert, Belgium, operates as a medical technology company dedicated to advancing solutions for sleep-disordered breathing conditions. The company's core mission revolves around addressing the significant unmet needs of patients suffering from obstructive sleep apnea (OSA), a chronic condition characterized by repeated pauses in breathing during sleep. Nyxoah has developed and commercialized the Genio system, its flagship product, which represents a patient-centric, hypoglossal neurostimulation therapy. This innovative system is designed to treat individuals with moderate to severe obstructive sleep apnea, offering an alternative to traditional continuous positive airway pressure (CPAP) machines, which many patients find difficult to adhere to. The Genio system has achieved CE-Mark status, signifying its conformity with European health, safety, and environmental protection standards, thereby allowing its commercialization within the European Economic Area. This certification underscores the system's clinical validation and readiness for market adoption. Hypoglossal neurostimulation therapy works by stimulating the hypoglossal nerve, which controls the muscles of the tongue and upper airway, to prevent airway collapse during sleep. Nyxoah's approach emphasizes a patient-centric design, aiming to enhance comfort, ease of use, and overall treatment adherence, which are critical factors for long-term therapeutic success in OSA management. The company's evolution since its incorporation has been focused on rigorous research and development, clinical validation, and strategic market entry to establish the Genio system as a viable and effective treatment option. Nyxoah's competitive positioning is rooted in its specialized neurostimulation technology and its commitment to improving the quality of life for OSA patients through innovative medical devices.

What Products and Services Does NYXH Offer?

• Develops and commercializes solutions for sleep-disordered breathing conditions.
• Offers the Genio system, a hypoglossal neurostimulation therapy.
• The Genio system is designed to treat moderate to severe obstructive sleep apnea (OSA).
• The Genio system is CE-Marked, indicating compliance with European health and safety standards.
• Focuses on a patient-centric approach to medical device design.
• Utilizes advanced neurostimulation technology to prevent airway collapse during sleep.
• Aims to provide an alternative treatment for OSA patients who struggle with traditional therapies.
• Headquartered in Mont-Saint-Guibert, Belgium, and incorporated in 2009.

How Does NYXH Make Money?

• Generates revenue primarily through the sale of its Genio system to healthcare providers.
• Focuses on commercialization within markets where its product holds regulatory approval (e.g., CE-Marked regions).
• Likely involves ongoing support and service for implanted devices, though not explicitly detailed.
• Invests heavily in research and development to enhance existing products and explore new solutions.

What Industry Does NYXH Operate In?

Nyxoah S.A. operates within the dynamic and evolving Medical - Instruments & Supplies industry, specifically targeting solutions for sleep-disordered breathing. The broader healthcare sector is witnessing increasing demand for advanced medical devices, driven by an aging global population, rising chronic disease prevalence, and technological innovation. Obstructive Sleep Apnea (OSA) represents a significant and often underdiagnosed condition, creating a substantial market for effective treatment alternatives. The market for sleep apnea devices, including CPAP machines, oral appliances, and implantable neurostimulation systems, is characterized by ongoing innovation aimed at improving patient comfort and adherence. Nyxoah's Genio system positions the company as a player in the neuromodulation segment of this market, offering a distinct therapeutic approach. Nyxoah competes with established players offering traditional therapies and other emerging neurostimulation technologies, necessitating continuous differentiation through clinical efficacy, patient experience, and market access strategies.

Who Are NYXH's Key Customers?

• Patients diagnosed with moderate to severe obstructive sleep apnea (OSA).
• Sleep specialists and pulmonologists who diagnose and treat sleep disorders.
• Ear, Nose, and Throat (ENT) surgeons who perform the Genio system implantation.
• Hospitals and sleep clinics that offer advanced treatment options for OSA.

Nyxoah S.A. Financial Trajectory

Nyxoah S.A. (NYXH) reported $8.9M in revenue for Q2 FY2026, reflecting 4.3% growth compared to the prior quarter. The company recorded a net loss of $38.2M, with diluted EPS of $-0.67. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company. Across the four most recent quarters, NYXH averaged $-0.64 in diluted EPS.

Company Profile

Nyxoah S.A. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Mont-Saint-Guibert, BE. The company is led by CEO Olivier Taelman. NYXH has traded publicly since 2021.

How Nyxoah S.A. Is Valued

Analyst price targets span from $2.31 to $7.00, with a consensus of $4.08. At the current price of $1.54, that implies approximately 165% upside potential. Relative to its peer group, NYXH's quantitative score of 15/100 is below the peer average of 73/100.

Key Financial Metrics

Return on assets is -87.9%, showing how much profit it generates from its asset base. A current ratio of 0.99 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -127.8%, the inverse of the P/E and a quick read on earnings relative to price.

Nyxoah S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.04 places it in the distress zone, a signal of elevated financial risk.

Nyxoah S.A. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 13.0% below estimates on average.

NYXH Financials

NYXH Latest News

NYXH Analyst Consensus

NYXH MoonshotScore

What Investors Ask About Nyxoah S.A. (NYXH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources